Literature DB >> 11895976

Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice.

Andre L Moreira1, Liana Tsenova, Melles Haile Aman, Linda-Gail Bekker, Sherry Freeman, Bande Mangaliso, Ulf Schröder, Jaishree Jagirdar, William N Rom, Michael G Tovey, Victoria H Freedman, Gilla Kaplan.   

Abstract

To control tuberculosis worldwide, the burden of adult pulmonary disease must be reduced. Although widely used, Mycobacterium bovis BCG vaccination given at birth does not protect against adult pulmonary disease. Therefore, postexposure vaccination of adults with mycobacterial antigens is being considered. We examined the effect of various mycobacterial antigens on mice with prior M. tuberculosis infection. Subcutaneous administration of live or heat-treated BCG with or without lipid adjuvants to infected mice induced increased antigen-specific T-cell proliferation but did not reduce the bacterial load in the lungs and caused larger lung granulomas. Similarly, additional mycobacterial antigen delivered directly to the lungs by aerosol infection with viable M. tuberculosis mixed with heat-killed Mycobacterium tuberculosis (1:1) also did not reduce the bacillary load but caused increased expression of tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6), which was associated with larger granulomas in the lungs. When M. tuberculosis-infected mice were treated with recombinant BCG that secreted cytokines shown to reduce disease in a preinfection vaccine model, the BCG secreting TNF-alpha, and to a lesser extent, IL-2 and gamma interferon (IFN-gamma), caused a significant increase in granuloma size in the lungs. Moreover, treatment of M. tuberculosis-infected mice with recombinant murine TNF-alpha resulted in increased inflammation in the lungs and accelerated mortality without affecting the bacillary load. Taken together, these studies suggest that administration of mycobacterial antigens to mice with prior M. tuberculosis infection leads to immune activation that may exacerbate lung pathology via TNF-alpha-induced inflammation without reducing the bacillary load.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895976      PMCID: PMC127838          DOI: 10.1128/IAI.70.4.2100-2107.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination.

Authors:  S Sreevatsan; X Pan; K E Stockbauer; N D Connell; B N Kreiswirth; T S Whittam; J M Musser
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.

Authors: 
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

3.  Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis.

Authors:  S L Baldwin; C D'Souza; A D Roberts; B P Kelly; A A Frank; M A Lui; J B Ulmer; K Huygen; D M McMurray; I M Orme
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  Oromucosal interferon therapy: pharmacokinetics and pharmacodynamics.

Authors:  P Eid; J F Meritet; C Maury; A Lasfar; D Weill; M G Tovey
Journal:  J Interferon Cytokine Res       Date:  1999-02       Impact factor: 2.607

5.  Vaccination against tuberculosis by DNA injection.

Authors:  R E Tascon; M J Colston; S Ragno; E Stavropoulos; D Gregory; D B Lowrie
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

6.  Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice.

Authors:  P Laochumroonvorapong; J Wang; C C Liu; W Ye; A L Moreira; K B Elkon; V H Freedman; G Kaplan
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

7.  rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo.

Authors:  B J Johnson; L G Bekker; R Rickman; S Brown; M Lesser; S Ress; P Willcox; L Steyn; G Kaplan
Journal:  Tuber Lung Dis       Date:  1997

8.  Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis.

Authors:  L G Bekker; G Maartens; L Steyn; G Kaplan
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

Review 9.  Vaccines, genes and trials.

Authors:  P E Fine
Journal:  Novartis Found Symp       Date:  1998

10.  Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis.

Authors:  A L Moreira; L Tsenova-Berkova; J Wang; P Laochumroonvorapong; S Freeman; V H Freedman; G Kaplan
Journal:  Tuber Lung Dis       Date:  1997
View more
  28 in total

1.  Cytokine expression profiles of bovine lymph nodes: effects of Mycobacterium bovis infection and bacille Calmette-Guérin vaccination.

Authors:  S Widdison; L J Schreuder; B Villarreal-Ramos; C J Howard; M Watson; T J Coffey
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 2.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 3.  Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection.

Authors:  Katrin D Mayer-Barber; Daniel L Barber
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-17       Impact factor: 6.915

4.  Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes.

Authors:  Shen-An Hwang; Katarzyna M Wilk; Yogesh A Bangale; Marian L Kruzel; Jeffrey K Actor
Journal:  Med Microbiol Immunol       Date:  2007-03-22       Impact factor: 3.402

5.  Effect of Mycobacterium tuberculosis-specific 10-kilodalton antigen on macrophage release of tumor necrosis factor alpha and nitric oxide.

Authors:  Vladimir Trajkovic; Gyanesh Singh; Balwan Singh; Sarman Singh; Pawan Sharma
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

Review 6.  Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control.

Authors:  Ted Cohen; Paul D van Helden; Douglas Wilson; Caroline Colijn; Megan M McLaughlin; Ibrahim Abubakar; Robin M Warren
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

7.  Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis.

Authors:  Andrea Cruz; Alexandra G Fraga; Jeffrey J Fountain; Javier Rangel-Moreno; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Troy D Randall; Jorge Pedrosa; Andrea M Cooper; António G Castro
Journal:  J Exp Med       Date:  2010-07-12       Impact factor: 14.307

8.  Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs.

Authors:  Samantha L Sampson; Christopher C Dascher; Vasan K Sambandamurthy; Robert G Russell; William R Jacobs; Barry R Bloom; Mary K Hondalus
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

9.  Proteins of the Rpf family: immune cell reactivity and vaccination efficacy against tuberculosis in mice.

Authors:  Vladimir V Yeremeev; Tatiana K Kondratieva; Elvira I Rubakova; Svetlana N Petrovskaya; Konstantin A Kazarian; Miroslav V Telkov; Sergej F Biketov; Arseny S Kaprelyants; Alexander S Apt
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis.

Authors:  Evelyn Guirado; Olga Gil; Neus Cáceres; Mahavir Singh; Cristina Vilaplana; Pere-Joan Cardona
Journal:  Clin Vaccine Immunol       Date:  2008-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.